IGI Laboratories Inc., a formulation and manufacturing company, announced that it has submitted an additional abbreviated new drug application (ANDA) to the US FDA, bringing the company’s total number of submissions to five.
IGI president and CEO Charlie Moore commented, “We are excited to have one additional ANDA filing for 2011. We now have five ANDAs on file with the US FDA, and we are poised to deliver a strong product development performance in 2012. ANDAs are the key to the future at IGI and our development team remains focused and motivated.” The development of ANDA products has successfully been integrated into the company’s ongoing contract services business.
IGI Laboratories is focused in the development and commercialization of products for the dermatology market.